Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in …
Biotechnology
US, San Carlos [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Vaxcyte, Inc. (PCVX) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 319,764.82 | 18,641.78 | 1,192.29 | 744.53 | 957.90 | 0.00 | 28.3392 | 42.55 | -0.7011 | -18.3613 | -0.07 | -0.08 | 6.0996 | - - | ||
| Maximum | - - | - - | - - | 39,973,011.00 | 881,933.00 | 85,592.00 | 99,050.00 | 262,089.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -233.7460 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0000 | - - | ||
| Akero Therapeutics, Inc. AKRO | 28.44 | -0.90 -3.07% | 27 vs. 591 | 1,985.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Apellis Pharmaceuticals, Inc. APLS | 32.99 | -0.22 -0.65% | 87 vs. 3,430 | 4,104.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
| BioMarin Pharmaceutical Inc. BMRN | 65.53 | -0.13 -0.20% | 56 vs. 1,492 | 12,488.00 | 648.00 | 88.00 | 12.00 | -532.00 | 0.4700 | 46.3847 | 0.0000 | 0.7850 | 0.1366 | 0.0175 | 0.0129 | 1.5477 | 190.00 | ||
| Nuvalent, Inc. NUVL | 83.18 | -1.04 -1.23% | 29 vs. 441 | 5,910.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 71.00 | ||
| Vaxcyte, Inc. PCVX | 86.15 | -0.38 -0.44% | 56 vs. 1,124 | 10,737.00 | 0.00 | -95.00 | -171.00 | -1,019.00 | -0.8500 | -19.6094 | 0.0000 | 0.0000 | 0.0000 | -0.0479 | -0.0454 | 17.2498 | 124.00 | ||
| Bio-Techne Corporation TECH | 72.55 | -0.62 -0.85% | 36 vs. 916 | 11,527.00 | 303.00 | 49.00 | 64.00 | 1,297.00 | 0.3100 | 55.6413 | 0.0012 | 0.6764 | 0.1617 | 0.0244 | 0.0180 | 2.4910 | 158.00 | ||
| DICE Therapeutics, Inc. DICE | 47.55 | 0.03 0.06% | 4,332 vs. 1,753 | 2,270.00 | 0.00 | -34.00 | -30.00 | -248.00 | -0.7400 | -15.7831 | 0.0000 | 0.0000 | 0.0000 | -0.0671 | -0.0632 | 25.6858 | 47.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.